2019-04-10

Positive results for Buvidal® in treatment for fentanyl dependence

New positive results from a Phase 3 study show that Camurus’ Buvidal® provides better treatment effect for fentanyl abuse, among other things, compared to other standard treatments as well as lower withdrawal and drug craving.

New positive results from a Phase 3 study show that Camurus’ Buvidal® provides better treatment effect for fentanyl abuse, among other things, compared to other standard treatments as well as lower withdrawal and drug craving.

Read more at Camurus’ website: https://www.camurus.com/pressreleases/

Latest news

2020-07-16

Camurus' Interim Report Second Quarter 2020

”For the fourth quarter in a row, we saw Buvidal® sales growth of more than 50%”

Read more

2020-06-24

Positive results from Phase 2 study

Positive results from Phase 2 study of once-weekly FluidCrystal® formulation of setmelanotide in healthy volunteers…

Read more

2020-06-23

Camurus raises full year 2020 revenue guidance

The improvements are driven by increasing market shares of Buvidal® for treatment of opioid dependence in Europe and…

Read more

2020-05-07

Camurus Interim Report January-March 2020

”The number of patients treated with Buvidal® increased by 90 percent in the quarter”

Read more

2020-04-08

Camurus Annual Report for 2019

Camurus Annual Report for 2019 is now available at the company´s website.

Read more